91 related articles for article (PubMed ID: 8671791)
21. Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up.
Ducloux D; Motte G; Billerey C; Bresson-Vautrin C; Vautrin P; Rebibou JM; Saint-Hillier Y; Chalopin JM
Transpl Int; 2002 Sep; 15(8):387-92. PubMed ID: 12221456
[TBL] [Abstract][Full Text] [Related]
22. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
Morales JM; Hartmann A; Walker R; Arns W; Senatorski G; Grinyó JM; Shoker A; Wilczek H; Jamieson NV; Lelong M; Brault Y; Burke JT; Scarola JA;
Transplant Proc; 2009; 41(6):2339-44. PubMed ID: 19715914
[TBL] [Abstract][Full Text] [Related]
23. Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation.
Sartori TM; Maurizio PG; Sara P; Ugolino L; Annalisa A; Panagiotis T; Massimo F; Antonio G
J Heart Lung Transplant; 1999 Jul; 18(7):693-700. PubMed ID: 10452346
[TBL] [Abstract][Full Text] [Related]
24. Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporine.
Hecking M; Kainz A; Schillinger M; Posch C; Birsan T; Rasoul-Rockenschaub S; Böhmig GA; Schmaldienst S; Watschinger B; Hörl WH; Mühlbacher F; Säemann MD
Transpl Int; 2008 Mar; 21(3):223-33. PubMed ID: 17903183
[TBL] [Abstract][Full Text] [Related]
25. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of plasminogen activator inhibitor-1 by angiotensin II receptor blockers on cyclosporine-treated renal allograft recipients.
Ishikawa A; Ohta N; Ozono S; Kawabe K; Kitamura T
Transplant Proc; 2005 Mar; 37(2):994-6. PubMed ID: 15848601
[TBL] [Abstract][Full Text] [Related]
27. Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications?
Badiou S; Garrigue V; Dupuy AM; Chong G; Cristol JP; Mourad G
Transplant Proc; 2006 Sep; 38(7):2314-6. PubMed ID: 16980076
[TBL] [Abstract][Full Text] [Related]
28. Effects of cyclosporin A and FK 506 on lipid metabolism and fibrinogen in kidney transplant recipients.
Hohage H; Arlt M; Brückner D; Dietl KH; Zidek W; Spieker C
Clin Transplant; 1997 Jun; 11(3):225-30. PubMed ID: 9193847
[TBL] [Abstract][Full Text] [Related]
29. Treatment with everolimus is associated with a procoagulant state.
Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
[TBL] [Abstract][Full Text] [Related]
30. Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients.
Grimbert P; Baron C; Fruchaud G; Hemery F; Desvaux D; Buisson C; Chopin D; Dahmane D; Remy P; Pastural M; Abbou C; Weil B; Lang P
Transpl Int; 2002 Nov; 15(11):550-5. PubMed ID: 12461659
[TBL] [Abstract][Full Text] [Related]
31. Modifying cyclosporine associated renal allograft dysfunction.
Mohapatra N; Vanikar AV; Patel RD; Trivedi HL
Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):770-4. PubMed ID: 19736471
[TBL] [Abstract][Full Text] [Related]
32. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
33. Impact of cyclosporin immunosuppression on serum magnesium and its fractional excretion in renal transplant recipients.
Nawaz SH; Zafar MN; Naqvi SA; Rizvi SA
J Pak Med Assoc; 2005 Mar; 55(3):98-100. PubMed ID: 15852743
[TBL] [Abstract][Full Text] [Related]
34. Renal sodium transporters are increased in urinary exosomes of cyclosporine-treated kidney transplant patients.
Esteva-Font C; Guillén-Gómez E; Diaz JM; Guirado L; Facundo C; Ars E; Ballarin JA; Fernández-Llama P
Am J Nephrol; 2014; 39(6):528-35. PubMed ID: 24942911
[TBL] [Abstract][Full Text] [Related]
35. Prospective randomized study of azathioprine vs cyclosporine based therapy in primary haplo-identical living-donor kidney transplantation: 20-year experience.
Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Sobh M; Ghoneim M
Clin Exp Nephrol; 2007 Jun; 11(2):151-155. PubMed ID: 17593515
[TBL] [Abstract][Full Text] [Related]
36. Safety of low-dose cyclosporine therapy before transplantation in kidney allograft recipients.
Khosroshahi HT; Badrogli N; Jahannavard N; Oskuii R; Bahluli A; Azar SA; Ardalan M
Transplant Proc; 2009 Sep; 41(7):2757-60. PubMed ID: 19765427
[TBL] [Abstract][Full Text] [Related]
37. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence.
Pham PT; Pham PC
Nephrol Dial Transplant; 2012 Jul; 27(7):2965-71. PubMed ID: 22207327
[TBL] [Abstract][Full Text] [Related]
38. Long-term use of cyclosporine A does not adversely impact on clinical outcomes following renal transplantation.
Lewis RM
Kidney Int Suppl; 1995 Dec; 52():S75-8. PubMed ID: 8587289
[TBL] [Abstract][Full Text] [Related]
39. ABCB1 G2677 allele is associated with high dose requirement of cyclosporin A to prevent renal allograft rejection in North India.
Singh R; Kesarwani P; Srivastava A; Mittal RD
Arch Med Res; 2008 Oct; 39(7):695-701. PubMed ID: 18760199
[TBL] [Abstract][Full Text] [Related]
40. Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation.
Brown JH; Murphy BG; Douglas AF; Short CD; Bhatnagar D; Mackness MI; Hunt LP; Doherty CC; Durrington PN
Nephron; 1997; 75(3):277-82. PubMed ID: 9069448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
